Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
2000
Pilot Study of a Specific Dietary Supplement inTumor-Bearing Mice and in Stage IIIB and IV Non-Small Cell Lung Cancer Patients
2001
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Doxorubicin pathways
2010 Standout
Chemotherapy for small cell lung cancer
2003
Non-Transgenic Mouse Models of Kidney Disease
2016 Standout
Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project
2008
Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer
2008
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited
2009
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial
1996
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
1996
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
2010
Anthrazykline in der Krebstherapie
1997 Standout
An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity
2011
Prediction of neurological outcome after cardiopulmonary resuscitation by serial determination of serum neuron-specific enolase
2006
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
1998
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy
1998
European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support
2010 Standout
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923
2002
Double-Cycle, High-Dose Ifosfamide, Carboplatin, and Etoposide Followed by Peripheral Blood Stem-Cell Transplantation for Small Cell Lung Cancer
2005
Microtubules as a target for anticancer drugs
2004 Standout
Cisplatin: The first metal based anticancer drug
2019 Standout
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
2000
Phase I/II Study of Stage III and IV Non-Small Cell Lung Cancer Patients Taking a Specific Dietary Supplement
1999
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Natural compounds for cancer treatment and prevention
2009 Standout
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
Small-cell lung cancer
2005
ROS and the DNA damage response in cancer
2018 Standout
Radiomics: Extracting more information from medical images using advanced feature analysis
2012 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Serum Neuron–specific Enolase as a Prognostic Marker for Irreversible Brain Damage in Comatose Cardiac Arrest Survivors
1996
EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer
2003
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
2009
Small-cell lung cancer
2011
Perspectives in cancer chemotherapy
2001
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Part 9: Post–Cardiac Arrest Care
2010 Standout
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Serum S-100 and Neuron-Specific Enolase for Prediction of Regaining Consciousness After Global Cerebral Ischemia
1998
Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
2010
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis*
2000 Standout
Phase III Comparative Study of High-Dose Cisplatin Versus a Combination of Paclitaxel and Cisplatin in Patients With Advanced Non–Small-Cell Lung Cancer
2000
Part 8: Post–Cardiac Arrest Care
2015 Standout
Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
2005
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions*
1997
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of M.C. Berchier being referenced
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party
2007
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
1996
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1998
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer (NSCLC)
1996
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
2007
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
1993
Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small cell lung cancer
1994
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics
2001
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer
1999
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer
2008
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party].
1997
A randomized trial comparing in small cell lung cancer (SCLC) induction chemotherapy by ifosfamide and etoposide with adriamycin (IVA) or epirubicine (IVE): An European lung cancer working party report
1993
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1994
A PHASE-II STUDY TESTING A COMBINATION CHEMOTHERAPY WITH EPIRUBICIN AND VINDESINE AS 2ND LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
1995
Monoclonal Immunoradiometric Assay and Polyclonal Radioimmunoassay Compared for Measuring Neuron-Specific Enolase in Patients with Lung Cancer
1992
Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: Experience of the European Lung Cancer Working Party
1995
161 Carboplatin prescribed in mg/m2 in patients with advanced non small cell lung cancer (NSCLC): Is there an impact of the reached area under the curve (AUC) on response, survival and hematological toxicity?
1997
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil
1994